Cargando…
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
BACKGROUND: The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with <30% and <70% of normal G6PD activity a...
Autores principales: | Watson, James, Taylor, Walter R. J., Bancone, Germana, Chu, Cindy S., Jittamala, Podjanee, White, Nicholas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931686/ https://www.ncbi.nlm.nih.gov/pubmed/29677199 http://dx.doi.org/10.1371/journal.pntd.0006440 |
Ejemplares similares
-
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Llanos-Cuentas, A., et al.
Publicado: (2019) -
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
por: Watson, James A, et al.
Publicado: (2022) -
Cost-Benefit Analysis of Tafenoquine for Radical Cure of Plasmodium vivax Malaria in Korea
por: Suh, Jiyeon, et al.
Publicado: (2022) -
Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency
por: Taylor, Walter R. J., et al.
Publicado: (2023) -
Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives
por: Markus, Miles B
Publicado: (2021)